Research on melanoma, including cutaneous, mucosal, and metastatic melanoma

From November 2025

Neoadjuvant immunotherapy shows promise in stage III melanoma, with accurate %RVT calculations (ref: Rawson doi.org/10.1016/j.annonc.2025.10.1237/).
Nivolumab and ipilimumab demonstrate a 63% overall response rate in advanced dMMR/MSI-H cancers (ref: Carlino doi.org/10.1001/jamaoncol.2025.4721/).
Tattoo exposure is associated with a 29% increased risk of cutaneous melanoma (ref: Rietz Liljedahl doi.org/10.1007/s10654-025-01326-6/).
Senescent fibroblasts enhance melanoma progression through GCP-2 secretion (ref: Basu doi.org/10.1111/acel.70239/).
AI-based biomarkers are being standardized for clinical use in oncology (ref: Aldea doi.org/10.1016/j.annonc.2025.11.009/).
Glycolysis-inhibiting microparticles enhance immunogenic cell death in melanoma (ref: Zhang doi.org/10.1016/j.biomaterials.2025.123832/).
No clear association between immune-related adverse events and survival in stage III melanoma (ref: Zablonski doi.org/10.1093/oncolo/).
Multi-gene panel testing and pembrolizumab coverage improve patient survival in metastatic melanoma (ref: Weymann doi.org/10.1093/jnci/).

Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec